In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus
Borris Rosnay Tietcheu Galani
Vincent Brice Ayissi Owona
Romeo Joel Guemmogne Temdie
Karoline Metzger
Marie Atsama Amougou
Pascal Dieudonné Djamen Chuisseu
Arnaud Fondjo Kouam
Marceline Ngounoue Djuidje
Cécile-Marie Aliouat-Denis
Laurence Cocquerel
Paul Fewou Moundipa
In Silico Pharmacology, 2021-12
Laurence Cocquerel
Cocquerel Laurence
ORCID: 0000-0002-2136-5178
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus
10.1128/jvi.00404-16
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/jvi.00192-15
SRFBP1, an Additional Player in HCV Entry
10.1016/j.tim.2015.08.003
CD81 and Hepatitis C Virus (HCV) Infection
10.3390/v6020535
Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein
10.1371/journal.pone.0111333
EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry
10.1111/cmi.12112
The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus
10.1002/hep.26273
Structural Basis of Ligand Interactions of the Large Extracellular Domain of Tetraspanin CD81
10.1128/jv1.00559-12
Hepatitis C virus entry into the hepatocyte
10.2478/s11535-011-0076-y
Interacting Regions of CD81 and Two of Its Partners, EWI-2 and EWI-2wint, and Their Effect on Hepatitis C Virus Infection
10.1074/jbc.M111.220103
The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry
10.1186/1471-2180-9-111
The Ig Domain Protein CD9P-1 Down-regulates CD81 Ability to Support Plasmodium yoelii Infection
10.1074/jbc.M109.057927
Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry
10.1111/j.1462-5822.2007.01070.x
Early steps of the hepatitis C virus life cycle
10.1111/j.1462-5822.2007.01107.x
Entry of HCV into target cells
10.1684/vir.2008.0163
The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
10.1371/journal.pone.0001866
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins
10.1099/vir.0.82872-0
Hepatitis C virus entry: potential receptors and their biological functions
10.1099/vir.0.81646-0
Kinetics of HCV envelope proteins' interaction with CD81 large extracellular loop
10.1016/j.bbrc.2005.01.056
Characterization of functional hepatitis C virus envelope glycoproteins
10.1128/jvi.78.6.2994-3002.2004
Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions
10.1074/jbc.M406315200
CD81-dependent binding of hepatitis C virus E1E2 heterodimers
10.1128/jvi.77.19.10677-10683.2003
Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody
10.1128/jvi.77.2.1604-1609.2003
Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line
10.1093/glycob/12.2.95
Subcellular localization and topology of the p7 polypeptide of hepatitis C virus
10.1128/jvi.76.8.3720-3730.2002
Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins
10.1093/emboj/cdf295
Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins
10.1128/jvi.74.8.3623-3633.2000
Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein
10.1074/jbc.M004326200
Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval
10.1074/jbc.273.48.32088
[Occludin, an additional key for hepatitis C virus entry].
10.1051/medsci/2009256-7549
HCV research 20 years after discovery: a summary of the 16th international symposium on hepatitis C virus and related viruses.
10.1053/j.gastro.2009.11.018
Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies.
10.1016/j.yexcr.2011.08.018
Structural basis of ligand interactions of the large extracellular domain of tetraspanin CD81.
10.1128/jvi.00559-12
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver.
10.1136/gutjnl-2015-311109
Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein.
10.1053/j.gastro.2017.09.020
The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization.
10.1074/jbc.m003003200
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication.
10.1111/cmi.12804
The Role of CD81 in HCV and Plasmodium Infection
10.1007/978-94-007-6070-7_14
Biogenesis of hepatitis C virus envelope glycoproteins
10.1099/0022-1317-82-11-2589
Endoplasmic reticulum retention of hepatitis C virus glycoprotein complex E1E2: A role for the transmembrane domain of E2
10.1016/s0248-4900(98)80287-6
Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2
10.1099/0022-1317-82-7-1629
SOLUTION STRUCTURE OF FRAGMENT (350-370) OF THE TRANSMEMBRANE DOMAIN OF HEPATITIS C ENVELOPE GLYCOPROTEIN E1
10.2210/pdb1emz/pdb
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle
10.1038/s41598-019-42737-2
Le virus de l’hépatite E, un virus méconnu qui se dévoile
10.1051/medsci/2018299
Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses
10.1099/jgv.0.001099
Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis
10.1093/infdis/jiz171
The fate of Hepatitis E virus capsid protein is regulated by an Arginine-Rich Motif
10.1101/2021.05.26.445820
In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus.
10.1007/s40203-021-00093-y
New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle
10.1101/435933
Borris Rosnay Galani Tietcheu
Galani Tietcheu Borris Rosnay
ORCID: 0000-0002-4324-5951
Hepatitis C in Cameroon: What is the progress from 2001 to 2016?
10.1515/jtim-2016-0037
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00488
Anti-Hepatitis C Virus Activity of Crude Extract and Fractions of Entada africana in Genotype 1b Replicon Systems
10.1142/s0192415x14500542
Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches
10.1155/2020/3807234
Investigation of dengue–malaria coinfection among febrile patients consulting at Ngaoundere Regional Hospital, Cameroon
10.1002/jmv.26732
In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus
10.1007/s40203-021-00093-y
